Drug intelligence / Profile preview

Restem-X

Development stage: Preclinical
Lead developer: Restem Group
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

Restem-X is an umbilical cord-derived mesenchymal progenitor cell (UMPC) therapy being developed by Restem for the treatment of osteoarthritis (OA). As a cell-based regenerative medicine, it utilizes the anti-inflammatory and tissue-reparative properties of mesenchymal progenitor cells to potentially address joint degeneration and associated pain. The therapy is designed to be administered locally to the affected joint to promote tissue repair and modulate the local immune environment. Restem-X is currently in the IND-enabling phase of development.

Beyond the preview

Go deeper on Restem-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Restem-X.

Explore the full profile